[General evaluation of adjuvant chemotherapy trials in breast cancer (excluding the Milan trial)].
In this general review of adjuvant chemotherapy clinical trial in breast cancer (with the exception of that of Milan), we shall try to answer the following questions: Is adjuvant chemotherapy useful and if so, for what precise purpose? Is polychemotherapy superior to monochemotherapy and if so, in what cases is it to be preferred? Can we determine the best time for beginning chemotherapy in relation to surgery? Could a shorter course of chemotherapy be equivalent to a longer one? Are there breast cancer subsets which particularly need adjuvant chemotherapy? After discussion of these questions, the answers are certainly affirmative although not perfectly outlined and the need for complementary trials is paramount if we want to obtain a consensus.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011379:Prognosis; D013997:Time Factors
D000970:Antineoplastic Agents
Bilan général des essais de chimiothérapie adjuvante dans le cancer du sein. (A l'exclusion de l'essai de Milan).